US institutional investors.
NeuroVive Pharmaceutical (publ) is a leading mitochondrial medicine company, engaged in the development of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. The addressable medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s share is listed on Nasdaq, Stockholm.
Directed issue to a number of US institutional investors of SEK 70 million to fund the commercialization and further development of NeuroVive’s product portfolio.